+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tasimelteon"

From
From
Autism Spectrum Disorder Pipeline Analysis Report 2025 - Product Thumbnail Image

Autism Spectrum Disorder Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Autistic Disorder- Pipeline Insight, 2025 - Product Thumbnail Image

Autistic Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Insomnia - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

Insomnia - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • February 2023
  • 198 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Tasimelteon is a drug used to treat circadian rhythm sleep disorders, such as Non-24-Hour Sleep-Wake Disorder (Non-24). It is a melatonin receptor agonist, meaning it works by mimicking the effects of the hormone melatonin. Tasimelteon is classified as a central nervous system (CNS) drug, and is used to help regulate the body's internal clock. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Non-24 in adults who are totally blind. Tasimelteon is part of a larger market of CNS drugs, which includes medications used to treat a variety of neurological conditions, such as depression, anxiety, and insomnia. These drugs are used to help regulate the brain's activity and improve mental health. Some companies in the Tasimelteon market include Vanda Pharmaceuticals, which manufactures and markets the drug, as well as other pharmaceutical companies that produce generic versions of the drug. Additionally, there are a number of companies that specialize in the research and development of CNS drugs, such as Neurocrine Biosciences and Otsuka Pharmaceuticals. Show Less Read more